Earlier this year, Martin Shrekli's actions following his purchase of Turing Pharmaceuticals were thought to be directly responsible for the bursting of the Wall Street biotech bubble, leading to a number of biotech IPO's being pulled and valuations reducing. Now it seems his activities may have caught up with him.